RESPIRATORY Medicine / Pulmonology Updates
الذهاب إلى القناة على Telegram
All the atest articles, research and news from worlds leading Pulmonology Journals. Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot
إظهار المزيد4 950
المشتركون
+124 ساعات
+167 أيام
+12030 أيام
جاري تحميل البيانات...
القنوات المماثلة
سحابة العلامات
الإشارات الواردة والصادرة
---
---
---
---
---
---
جذب المشتركين
يوليو '26
يوليو '26
+71
في 0 قنوات
يونيو '26
+139
في 0 قنوات
Get PRO
مايو '26
+160
في 0 قنوات
Get PRO
أبريل '26
+158
في 0 قنوات
Get PRO
مارس '26
+107
في 0 قنوات
Get PRO
فبراير '26
+110
في 0 قنوات
Get PRO
يناير '26
+98
في 0 قنوات
Get PRO
ديسمبر '25
+102
في 0 قنوات
Get PRO
نوفمبر '25
+112
في 2 قنوات
Get PRO
أكتوبر '25
+38
في 1 قنوات
Get PRO
سبتمبر '25
+2
في 0 قنوات
Get PRO
أغسطس '25
+7
في 0 قنوات
Get PRO
يوليو '25
+8
في 0 قنوات
Get PRO
يونيو '25
+7
في 1 قنوات
Get PRO
مايو '25
+8
في 0 قنوات
Get PRO
أبريل '25
+13
في 0 قنوات
Get PRO
مارس '25
+11
في 0 قنوات
Get PRO
فبراير '25
+19
في 0 قنوات
Get PRO
يناير '25
+36
في 1 قنوات
Get PRO
ديسمبر '24
+58
في 0 قنوات
Get PRO
نوفمبر '24
+237
في 3 قنوات
Get PRO
أكتوبر '24
+214
في 0 قنوات
Get PRO
سبتمبر '24
+170
في 0 قنوات
Get PRO
أغسطس '24
+144
في 0 قنوات
Get PRO
يوليو '24
+82
في 1 قنوات
Get PRO
يونيو '24
+85
في 0 قنوات
Get PRO
مايو '24
+62
في 1 قنوات
Get PRO
أبريل '24
+58
في 0 قنوات
Get PRO
مارس '24
+53
في 0 قنوات
Get PRO
فبراير '24
+121
في 0 قنوات
Get PRO
يناير '24
+192
في 0 قنوات
Get PRO
ديسمبر '23
+229
في 0 قنوات
Get PRO
نوفمبر '23
+47
في 0 قنوات
Get PRO
أكتوبر '23
+66
في 3 قنوات
Get PRO
سبتمبر '23
+40
في 0 قنوات
Get PRO
أغسطس '23
+72
في 0 قنوات
Get PRO
يوليو '23
+62
في 0 قنوات
Get PRO
يونيو '23
+70
في 0 قنوات
Get PRO
مايو '23
+69
في 0 قنوات
Get PRO
أبريل '23
+68
في 0 قنوات
Get PRO
مارس '23
+80
في 0 قنوات
Get PRO
فبراير '23
+67
في 0 قنوات
Get PRO
يناير '23
+80
في 0 قنوات
Get PRO
ديسمبر '22
+87
في 0 قنوات
Get PRO
نوفمبر '22
+265
في 0 قنوات
Get PRO
أكتوبر '22
+68
في 0 قنوات
Get PRO
سبتمبر '22
+96
في 0 قنوات
Get PRO
أغسطس '22
+72
في 0 قنوات
Get PRO
يوليو '22
+79
في 0 قنوات
Get PRO
يونيو '22
+119
في 0 قنوات
Get PRO
مايو '22
+125
في 0 قنوات
Get PRO
أبريل '22
+127
في 0 قنوات
Get PRO
مارس '22
+61
في 0 قنوات
Get PRO
فبراير '22
+35
في 0 قنوات
Get PRO
يناير '22
+49
في 0 قنوات
Get PRO
ديسمبر '21
+25
في 0 قنوات
Get PRO
نوفمبر '21
+39
في 0 قنوات
Get PRO
أكتوبر '21
+48
في 0 قنوات
Get PRO
سبتمبر '21
+29
في 0 قنوات
Get PRO
أغسطس '21
+39
في 0 قنوات
Get PRO
يوليو '21
+50
في 0 قنوات
Get PRO
يونيو '21
+74
في 0 قنوات
Get PRO
مايو '21
+41
في 0 قنوات
Get PRO
أبريل '21
+192
في 0 قنوات
Get PRO
مارس '21
+250
في 0 قنوات
Get PRO
فبراير '21
+41
في 0 قنوات
Get PRO
يناير '21
+60
في 0 قنوات
Get PRO
ديسمبر '20
+703
في 0 قنوات
| التاريخ | نمو المشتركين | الإشارات | القنوات | |
| 15 يوليو | +4 | |||
| 14 يوليو | +3 | |||
| 13 يوليو | +5 | |||
| 12 يوليو | +2 | |||
| 11 يوليو | +5 | |||
| 10 يوليو | +3 | |||
| 09 يوليو | +5 | |||
| 08 يوليو | +5 | |||
| 07 يوليو | +6 | |||
| 06 يوليو | +3 | |||
| 05 يوليو | +3 | |||
| 04 يوليو | +5 | |||
| 03 يوليو | +11 | |||
| 02 يوليو | +5 | |||
| 01 يوليو | +6 |
منشورات القناة
[Personal View] The role of sweat chloride in determining CFTR protein restoration in people with cystic fibrosis
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00159-1/fulltext?rss=yes
Sweat chloride concentrations are elevated in people with cystic fibrosis due to the absence or dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, an epithelial cell membrane ion channel. For many people with cystic fibrosis with responsive variants and drug access, treatment with CFTR modulators increases CFTR function, reduces sweat chloride concentrations, and improves lung health and quality of life. In clinical trials, average sweat chloride reduction is correlated with clinical efficacy across different modulators and study populations.
| 2 | [Position Paper] Reproductive health guidance for the cystic fibrosis community: a Cystic Fibrosis Foundation Position Paper
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00120-7/fulltext?rss=yes
The Cystic Fibrosis Foundation organised a multidisciplinary committee to develop this Position Paper to outline current knowledge and best practices in reproductive health care for individuals with cystic fibrosis. Working groups reviewed the literature and provided relevant guidance on reproductive health services, fertility, contraception, preconception and pregnancy, and cystic fibrosis transmembrane conductance regulator (CFTR) modulator exposure in utero and during lactation. Findings included: (1) reproductive health-care provision should be standardised, and education should begin at cystic fibrosis diagnosis and revisited annually; (2) contraception is safe overall, but underutilised in those with cystic fibrosis compared with the general population; (3) fertility might be improving with CFTR modulators for females with cystic fibrosis, but not for males with cystic fibrosis—assisted reproductive technologies are still required for males to achieve biological parenthood; (4) pregnancy requires close monitoring and unique screening for diabetes; and (5) CFTR modulator exposure in utero has implications for infant monitoring and cystic fibrosis screening results in newborns. | 116 |
| 3 | 🔴 Noninvasive Respiratory Support for Adult Patients with Acute Respiratory Failure
: 2026 ATS Guidelines
Updates in Medicine
July 2026 #medicalguidelines
@Updates_in_Medicine | 275 |
| 4 | [Correspondence] COPA syndrome: a monogenic mimic of rheumatoid arthritis-associated ILD that warrants inclusion in future consensus statements
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00220-1/fulltext?rss=yes
We read with great interest the expert consensus statement by Joshua J Solomon and colleagues on the screening, diagnosis, and management of rheumatoid arthritis-associated interstitial lung disease (ILD).1 Their Position Paper addresses genetic risk factors, including variants shared with idiopathic pulmonary fibrosis such as the MUC5B promoter polymorphism and rare variants in TERT, RTEL1, PARN, and SFTPC. We highlight an unmentioned monogenic condition: COPA (coatomer subunit α) syndrome. | 355 |
| 5 | [Comment] Beyond eosinophils: redefining asthma exacerbations in the biologic era
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00194-3/fulltext?rss=yes
The introduction of biologic therapies for severe asthma has transformed clinical practice. Among these agents, benralizumab occupies a unique position. By targeting the interleukin-5 receptor α, benralizumab induces near-complete depletion of circulating eosinophils and substantially reduces exacerbation risk.1 Yet, even among patients with excellent biological responses, exacerbations continue to occur. Why these events persist remains an important unanswered question in severe asthma. In this issue of The Lancet Respiratory Medicine, Jennifer Logan and colleagues report findings from the BenRex study,2 a prospective, multicentre cohort specifically designed to characterise exacerbations occurring during benralizumab treatment. | 363 |
| 6 | [Articles] Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00142-6/fulltext?rss=yes
The dual-oral chemotherapy-free regimen of ifebemtinib plus garsorasib had encouraging efficacy with a manageable safety profile as first-line treatment for KRASG12C-mutated NSCLC. A randomised phase 3 study has been initiated to further validate these findings against standard-of-care in the first-line setting (NCT07174908). | 372 |
| 7 | [Comment] FAK co-inhibition in KRASG12C-mutated non-small-cell lung cancer
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00184-0/fulltext?rss=yes
The therapeutic strategy of targeting KRASG12C mutations has yielded response rates of 28–56% and median progression-free survival of 5·6–13·8 months in pretreated non-small-cell lung cancer (NSCLC).1 Yet response durability remains poor in most patients, restricting broader use, particularly in first-line settings. Resistance emerges early during treatment through intrinsic or acquired mechanisms, such as adaptive RAS–MAPK reactivation, bypass-pathway signalling, and stromal-mediated and microenvironment-mediated escape. | 317 |
| 8 | [Personal View] Asthma diagnosis in adults and children: challenges, future directions, and a call to action
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00143-8/fulltext?rss=yes
Asthma is the most common chronic airway disease worldwide, imposing substantial clinical, societal, and economic burden. Asthma is generally defined as a heterogeneous clinical syndrome characterised by fluctuating respiratory symptoms and variable expiratory airflow limitation. Despite this definition, asthma misdiagnosis remains high; 20–70% of individuals with asthma remain undiagnosed and untreated, and approximately 30% of those labelled as having asthma do not have the disease. Objective evidence, alongside variability of symptoms, is essential to support a diagnosis of asthma. | 357 |
| 9 | [Articles] PERC-Peds rule for bedside exclusion of pulmonary embolism without radiation in children in the USA (BEEPER): a multicentre, prospective, observational, diagnostic accuracy study
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00086-X/fulltext?rss=yes
In this multicentre, prospective, observational, diagnostic accuracy study of children with suspected pulmonary embolism in the emergency department, we found a 6·3% prevalence of pulmonary embolism or proximal DVT; in this population, the PERC-Peds negative rule can safely rule out pulmonary embolism. Use of PERC-Peds might reduce low-value diagnostic testing for pulmonary embolism in children and adolescents. | 478 |
| 10 | [Comment] Intensive care in global conflicts: brace for impact
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00186-4/fulltext?rss=yes
Not a day goes by without the news reporting new and ongoing conflicts globally. Over the past few decades, the frequency and complexity of both intrastate and interstate conflicts have increased, with consequences extending beyond geopolitical boundaries into everyday life, including health-care systems.1 This evolving context raises the question of what the implications are for health-care professionals in the intensive care unit (ICU). | 401 |
| 11 | [Comment] The PERC-Peds rule: a promising step towards structured pulmonary embolism risk assessment in children
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00222-5/fulltext?rss=yes
Pulmonary embolism accounts for 10–15% of all paediatric venous thromboembolism (VTE) events, with an annual incidence of 0·14–0·9 per 100 000 children.1,2 Although rare, pulmonary embolism is a severe and potentially life-threatening complication in children.1 In adults, efforts to improve pulmonary embolism diagnosis have focused on increasing the accuracy of risk-stratification tools to reduce unnecessary testing and overtreatment.3 By contrast, in children, the main challenge has been delayed recognition and underdiagnosis. | 377 |
| 12 | [News] RSV vaccination and immunisation programmes accelerating worldwide
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00223-7/fulltext?rss=yes
Respiratory syncytial virus (RSV) has been a continuous and major cause of morbidity and mortality in babies and older people, adding pressure to strained hospitals in their busy winter seasons in countries of all incomes, while of course causing the highest mortality in low-income and middle-income countries (LMICs). According to WHO estimates, each year, RSV causes more than 3·6 million hospitalisations and around 100 000 deaths in children under 5 years of age. Most paediatric RSV deaths (97%) occur in LMICs where there is limited access to supportive medical care. | 348 |
| 13 | [Correspondence] Precision-guided immunomodulatory therapy in sepsis
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00153-0/fulltext?rss=yes
Erik H A Michels and colleagues developed a parsimonious three-biomarker framework (procalcitonin, soluble TREM-1, and IL-6) that quantifies the Dysregulated Immune Profile (DIP) as a continuous score (cDIP) beyond organ-failure-based clinical surrogates and identifies patients with differential responses to hydrocortisone.1 | 456 |
| 14 | [Correspondence] Precision-guided immunomodulatory therapy in sepsis – Authors’ reply
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00155-4/fulltext?rss=yes
We agree with Yingying Yang and colleagues that similar continuous Dysregulated Immune Profile (cDIP) values could arise from different host–pathogen configurations. Robustly decomposing immune dysregulation into discrete pathogen-driven versus host-driven components is challenging, as these processes are intrinsically coupled. Pathogen burden, identity, and infection source undoubtedly shape the host response, yet substantial heterogeneity in immune dysregulation persists within each of these factors (see appendix 2 p 39 of the original Article1). | 446 |
| 15 | [Correspondence] Precision-guided immunomodulatory therapy in sepsis
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00154-2/fulltext?rss=yes
We commend Erik H A Michels and colleagues1 for quantifying immune dysregulation in pneumonia and sepsis. Through dimensionality reduction and clustering with 35 biomarkers, they defined three Dysregulated Immune Profiles (DIPs) and a corresponding continuous score (cDIP). By training parsimonious models with three biomarkers, they facilitated the application of these clusters and score to datasets without extensive data, such as a subset (n=425) of the CAPE-COD trial2 (hydrocortisone vs placebo in community-acquired-pneumonia). | 375 |
| 16 | [Editorial] Dying with Dignity—time to cut the red tape
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00198-0/fulltext?rss=yes
While death is a certainty for us all, how and when we die is not. For people with a terminal illness, the reality of death must be confronted alongside common fears of prolonged pain and suffering as well as a loss of autonomy. Although good end-of-life care can manage most symptoms, there are some circumstances that cannot be palliated and a person might feel their quality of life is so poor they would prefer to die. The practice of medical aid in dying (MAiD; also called physician assisted death) allows someone with a terminal diagnosis to obtain medication from a physician to end their life. | 387 |
| 17 | [News] 2026 GINA report for asthma
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00188-8/fulltext?rss=yes
On May 5, 2025, the Global Initiative For Asthma (GINA) published the 2026 update to their Global Strategy for Asthma Management and Prevention. On the same date, an online discussion hosted by GINA panel members and the European Respiratory Society gave an overview of the major changes. | 359 |
| 18 | [Comment] Heterogeneity of severe asthma in Europe: a SHARP-er view
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00165-7/fulltext?rss=yes
Disease-modifying anti-asthmatic drugs, especially biologics, have fundamentally changed the therapeutic landscape of severe asthma, making asthma remission a realistic treatment goal in many patients.1 Although asthma remission concepts continue to evolve, definitions include minimal asthma symptoms, no exacerbations, no use of systemic corticosteroids, and stable or normal lung function, for at least 12 months.2 It has become evident that several challenges reduce remission rates in patients with severe asthma. | 568 |
| 19 | [Articles] Prevalence and disease trajectories of pulmonary fibrosis of childhood interstitial lung disease: a register-based, multicentre observational study
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00052-4/fulltext?rss=yes
The application of standardised criteria for diagnosing pulmonary fibrosis enables identification of affected children among patients with chILD. These children have lower pulmonary function, an increased risk of death, and could benefit from antifibrotic therapies. | 519 |
| 20 | [Articles] Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma Registry
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00141-4/fulltext?rss=yes
This pan-European analysis of severe asthma revealed significant clinical heterogeneity and a substantial disease burden despite advanced therapies, highlighting the enduring nature of type 2 inflammation, the potential inadequacy of current remission strategies with available therapeutic approaches, and the necessity for early identification of high-risk patients. | 475 |
